C Difficile Infection

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

A South Korea in-hospital assessment found that approximately half of all ordered CDI tests did not meet recommendation standards.

New data suggest prediction of SARS-CoV-2 and bacterial co-infection or superinfection could be provided for hospitalized patients.

New-onset diarrhea is common among inpatients and residents of long-term care facilities.

The most common diagnoses were found to be non-malignant, including upper gastrointestinal problems in men and urinary tract infections in women.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.

These signatures were also related to unfavorable stress responses related to gastrointestinal symptoms.

The new guidance restructures how study designers should look at trial population, efficacy benchmarks, and safety in clinical trials involving drug development.

Propolis is a resinous give product collected by honeybees from varied petals and plant buds sources.

A combination of first-line management consisting of validation, explanation, and a positive diagnosis, non-pharmacological treatments, and pharmacological treatment should be considered for pediatric patients with IBS or functional abdominal pain disorders.

Antibiotic and proton pump inhibitor use was also associated with an increased risk of C difficile infection.

Pediatric patients with CDI had a higher number of previous-day hospital admissions, hospitalizations, and total hospital admissions.

There were key aspects that differed in the gut microbiota between patients with major depressive disorder and the healthy control group.

A large proportions of patients with C difficile infections do not respond to metronidazole.

New research shows diarrhea did not increase overall mortality for hospitalized patients.

C Difficile infections decreased in VA healthcare facilities during the COVID-19 pandemic.

Recurrent infections occurred in 23.9% of the 134-patient study.

While it is known that ASD is linked to altered gut microbiota, there is little research into the altered bacterial species.

After 15 years and 18 patents, the new biotechnology developed by Ariste Medical receives FDA approval to assist in healing ventral hernia repair, one of the most common surgeries.

Fecal microbiota transplantation is known to cure up to 88% of patients with recurrent C difficile infections.

RBX2660 is a live microbiome therapeutics that could build on the success of fecal microbiota transplantation for treating patients with recurrent C difficile infections.

There was an independent association between in-hospital mortality and a neutrophil ratio greater than 75%, serum creatinine of at least 1.5 mg/L, and CDI caused by isolates harboring the tcdC gene.

The investigators assessed and validated 3 rule-based algorithms for C difficile infection detection.